Resources from the same session
LBA10 - Amivantamab plus lazertinib vs osimertinib as first-line treatment among Asian patients with <italic>EGFR</italic>-mutated, advanced non-small cell lung cancer (NSCLC): MARIPOSA subgroup analysis
Presenter: Hidetoshi Hayashi
Session: Proffered Paper session: Thoracic cancer
Resources:
Abstract
Slides
Webcast
LBA11 - Amivantamab plus chemotherapy vs chemotherapy among Asian patients with <italic>EGFR</italic>-mutant advanced NSCLC after progression on osimertinib: A MARIPOSA-2 subgroup analysis
Presenter: Victor Lee
Session: Proffered Paper session: Thoracic cancer
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA10 and LBA11
Presenter: Noemi Reguart Aransay
Session: Proffered Paper session: Thoracic cancer
Resources:
Slides
Webcast
LBA12 - Efficacy and safety of IBI351 (GFH925), a selective KRASG12C inhibitor, monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): Initial results from a registrational phase II study
Presenter: Jiaxin Lin
Session: Proffered Paper session: Thoracic cancer
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA12
Presenter: Jordi Remon Masip
Session: Proffered Paper session: Thoracic cancer
Resources:
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Proffered Paper session: Thoracic cancer
Resources:
Webcast